Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

This was the stock's second consecutive day of losses.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

Bristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

The stock's fall snapped a four-day winning streak.